{"transactions":[{"id":4613369,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:33.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001104659-26-106342","document":"tm2625057-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465926106342/tm2625057-7_4seq1.xml","form_type":"4"}},{"id":4613368,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:33.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001104659-26-106342","document":"tm2625057-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465926106342/tm2625057-7_4seq1.xml","form_type":"4"}},{"id":4613367,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:33.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-26-106342","document":"tm2625057-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465926106342/tm2625057-7_4seq1.xml","form_type":"4"}},{"id":4613366,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:33.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-26-106342","document":"tm2625057-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465926106342/tm2625057-7_4seq1.xml","form_type":"4"}},{"id":4613365,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:33.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2031-05-01","underlying":"Ordinary Shares","underlying_shares":34328},"source":{"system":"sec-edgar","filing":"0001104659-26-106342","document":"tm2625057-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465926106342/tm2625057-7_4seq1.xml","form_type":"4"}},{"id":4613364,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:20:33.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-106342","document":"tm2625057-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465926106342/tm2625057-7_4seq1.xml","form_type":"4"}},{"id":1115164,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-11T17:13:23.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) June 10, 2026 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":20174,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001828185-25-000041","document":"wk-form4_1749676396.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000182818525000041/wk-form4_1749676396.xml","form_type":"4"}},{"id":1517680,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-14T16:21:16.000Z","date":"2024-05-10","kind":"grant","planned":false,"acquired":true,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 10, 2025 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19516,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001828185-24-000056","document":"wk-form4_1715718060.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000182818524000056/wk-form4_1715718060.xml","form_type":"4"}},{"id":1842779,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-06-28T07:52:00.000Z","date":"2023-06-26","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.44,"value":24400.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":23000,"source":{"system":"sec-edgar","filing":"0001104659-23-075562","document":"tm2319828-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465923075562/tm2319828-1_4seq1.xml","form_type":"4"}},{"id":1895252,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-05-12T16:07:18.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 11, 2024 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19197,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-23-059727","document":"tm2315647-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465923059727/tm2315647-5_4seq1.xml","form_type":"4"}},{"id":2022925,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-10T16:40:48.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option shall vest and become exercisable on June 15, 2023, with the remainder vesting in 24 equal monthly installments thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":18604,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-23-018609","document":"tm236344-5_5seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465923018609/tm236344-5_5seq1.xml","form_type":"5"}},{"id":2308726,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-04-04T16:31:32.000Z","date":"2022-04-01","kind":"purchase","acquired":true,"shares":10000,"price":5.09,"value":50900.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":13000,"source":{"system":"sec-edgar","filing":"0001104659-22-042245","document":"tm2211410-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465922042245/tm2211410-2_4seq1.xml","form_type":"4"}},{"id":2725280,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-05-06T16:26:39.000Z","date":"2021-05-04","kind":"purchase","acquired":true,"shares":3000,"price":17,"value":51000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001104659-21-062426","document":"tm2115262-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465921062426/tm2115262-3_4seq1.xml","form_type":"4"}},{"id":2730530,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":78630,"kind":"person","name":"Scheeren Joseph","position":1,"cik":"0001852070","reported_name":"Scheeren Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2021-05-04T20:27:30.000Z","date":"2021-04-29","kind":"grant","acquired":true,"shares":34328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":34328,"derivative":{"exercise_price":17,"expiration_date":"2031-04-29","underlying":"Ordinary Shares","underlying_shares":34328},"source":{"system":"sec-edgar","filing":"0001104659-21-061228","document":"tm2114558-24_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852070/000110465921061228/tm2114558-24_4seq1.xml","form_type":"4"}}]}